MULTIPLE MYELOMA

A second interim analysis of the phase 3 Karmma-3 trial demonstrated significantly improved progression-free survival and overall response rates, compared with standard regimens, in patients with triple-class-exposed relapsed/refractory multiple myeloma.

A single-center, retrospective study demonstrated high rates of chronic opioid use after autologous stem cell transplantation in patients with multiple myeloma, also leading to inferior overall survival at 6 months of follow-up.

Treatment with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel is safe and effective for patients with relapsed/refractory multiple myeloma.

Krina Patel, MD, MSc, explains which patients with relapsed/refractory multiple myeloma she would not treat with CAR T-cell therapy, and the options after disease progression on CAR-T.

A look at BCMA targeting in relapsed/refractory multiple myeloma treatment and the BCMA-directed bispecific antibody teclistamab.

Ben Derman, MD, discussed results from a trial investigating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

Dr Sagar Lonial presents the case of a 58-year-old man with relapsed/refractory multiple myeloma to the panel for discussion.

Sagar Lonial, MD, FACP, provides an overview of the potential treatment options for patients with relapsed/refractory multiple myeloma.

In separate live, virtual events, David Dingli, MD, PhD, and Douglas W. Sborov, MD, MS, discussed with participants how they would treat a patient with multiple myeloma in accordance with the available therapeutic regimens.

After the results of the phase 2 KarMMa trial showed that idecabtagene vicleucel is a new standard of care in relapsed/refractory multiple myeloma, a real-world analysis continues to show the CAR T-cell therapy could have a wider reach.

During a Targeted Oncology case-based roundtable event, Amandeep Godara, MD, discussed the use of maintenance therapy for patients with multiple myeloma. This is the second of 2 articles based on this event.

The phase 1 POLARIS trial showed a 100% overall response rate for OriCAR-017, a novel CAR T-cell therapy with a new target in relapsed/refractory multiple myeloma.

Ben Derman, MD, discussed the rationale for an ongoing clinical trial evaluating minimal residual disease–guided discontinuation of maintenance therapy in patients with multiple myeloma.

Dr Srdan Verstovsek discusses how ruxolitinib might fit into the myelofibrosis treatment landscape in the future, and highlights remaining unmet needs.

Srdan Verstovsek, MD, reviews data presented at ASH 2022 on combination ruxolitinib and selinexor for the frontline treatment of myelofibrosis.

Dr Srdan Verstovsek, MD, details how the JAK-STAT pathway is utilized in the treatment of myelofibrosis.

Srdan Verstovsek, MD, provides an overview of myelofibrosis and the clinical signs and symptoms to look for.

Dr Joshua Richter explains which patients with multiple myeloma are most suitable for triplet combination therapies.

Joshua Richter, MD, highlights key data from an update to a study investigating a selinexor triplet combination therapy.

Dr Joshua Richter explains triple class refractory myeloma and the need for more data on treatment options.

Joshua Richter, MD, reviews data from two clinical trials investigating selinexor combination therapies for the treatment of multiple myeloma.

Dr Joshua Richter describes the mechanism of action of XPO1 inhibitor selinexor and its use in treating multiple myeloma.

Joshua Richter, MD, gives an overview of relapse/refractory multiple myeloma and the available treatment options.

Cilta-cel improved progression-free survival in relapsed/refractory multiple myeloma, according to findings from the first prespecified interim analysis of the phase 3 CARTITUDE-4 study.

Emma Searle, PhD, discusses results of the MajestTEC-2 trial combining teclistamab with daratumumab and lenalidomide for patients with multiple myeloma presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

Dr Peter Voorhees outlines advice for community oncologists who treat patients with R/R multiple myeloma.

Dr Voorhees shares his perspective on bispecifics, ADCs, and CAR T-cell therapy in the treatment landscapes of R/R multiple myeloma.

Dr Peter Voorhees highlights MonumenTAL-1, discussing management of notable adverse events and health-related quality of life outcomes from patients with R/R multiple myeloma.

Dr Peter Voorhees reviews bispecifics under development and updated outcomes data from the MonumenTAL-1 trial, evaluating talquetamab in patients with R/R multiple myeloma.

Peter Voorhees, MD, presents a case of a 63-year-old man with R/R multiple myeloma, shares his initial impressions, and discusses the assessment of clinical relapse in patients with R/R multiple myeloma.